Yujun Wei – InmunoES

Superior outcomes with offspring B-leader-matched haploidentical versus older matched sibling donors in AL/MDS patients aged ≥40 years

26 de August de 2026 by Yujun Wei

IntroductionWith advancing safety profiles in allogeneic hematopoietic stem cell transplantation (allo-HSCT), determining whether HLA-matched siblings remain the optimal donor choice for older adults (≥40 years) and whether haploidentical-HSCT demonstr…

Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes

18 de August de 2025 by Yujun Wei

PurposeRelapse remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome-IB (MDS-IB) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ruxolitinib has demonstrated …